Skip to main content
. 2013 Jul 15;8(7):e68469. doi: 10.1371/journal.pone.0068469

Figure 3. Cell viability and proliferation were examined in human glioma cells treated with miR-326 precursor.

Figure 3

A172 (A) and U373 (B) cells were transfected with miR-326 precursor, control precursor, NOB1 shRNA or nothing for 72 h as described in the methods section before measurement of the conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to a colored formazan product. A statistically significant delay of cell proliferation was observed after day 3. A172 cells (C) and U373 cells (D) were transfected with miR-326 precursor, control precursor, NOB1 shRNA or nothing for 72 h as described in the methods section, and the BrdU incorporation assay was performed. BrdU incorporation was decreased in the miR-326 group and NOB1-shRNA group compared to the controls at 72 h. Data represent the mean ± SD of three independent experiments. Significant differences between transfected cells and mock-infected cells were determined using the two-tailed Student’s t-test (*P<0.05, **P<0.01).